The 1st Coronavirus Vaccine has been discovered for experimental testing in United states of America.
The new vaccine is a collaboration between NIAID scientists and the biotechnology company Moderna Inc., based in Cambridge, Massachusetts.
Covid-19 which is the disease caused by Coronavirus has been a threat to human lives and National Economy systems. However, it seems that we are getting close to eliminating this deadly virus.
The vaccine was fast-tracked to human trials, but more time is needed before it’s ready for public use. A healthy volunteer in Seattle is the first person in the U.S.A. to receive a dose of an experimental coronavirus vaccine as part of a new clinical trial announced by the government health officials on March 16th.
The National Institute of Allergy and Infectious Diseases (NIAID) allowed the new vaccine to be fast-tracked into clinical trials without thorough testing in animal models, which usually stands as a strict prerequisite to human testing. While making the jump to human trials could bring the vaccine to market faster, this is only step one.
In the next 6 weeks, researchers plan to enroll 45 participants in the trial, which will test the safety of the vaccine as well as its ability to induce an immune response in the volunteers. The trial will be taking place at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.
However, NIAID Director Dr. Anthony Fauci told the House Oversight and Reform Committee that this new Vaccine must pass through 3 iterative phases of clinical trials before being deemed safe and effective for widespread use. Assuming the initial tests go well, it may take 12 to 18 months before any vaccine is ready for public use.
“Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority,” Fauci said in a NIAID statement, published March 16. “This Phase 1 study, launched in record speed, is an important first step toward achieving that goal.”
PHASE 1 TRIAL:
According to the U.S. Food and Drug Administration (FDA), this trial launched today is known as a “Phase 1 clinical trial,” meaning its main purpose is to provide information about how the vaccine interacts with a healthy human body.
Phase 1 trials examine a small group of people, typically between 20 and 80 individuals, who received different doses of an experimental treatment. Over the course of several months, researchers monitor how each volunteer metabolizes the given treatment and what common side effects emerge in response to different doses.
The 45 volunteers in the new trial will receive varying doses of the new vaccine called ‘mRNA-1273’ and they will be monitored over a 14-month period.
Volunteers will receive two injections of the vaccine in the upper arm, with a 28-day gap between doses. The first participant will receive the lowest dose of the vaccine, at 25 micrograms (mcg) per injection, according to the NIAID statement.
Three others will receive the same initial dose, and four more will each receive a 100-mcg dose of the vaccine and be thoroughly evaluated before any volunteers are given their second dose.
According to ClinicalTrials.gov., if participants’ reactions to the low doses prove acceptable, a third group of participants will receive 250 mcg of the vaccine per injection. In addition to monitoring for side effects, the researchers will test whether the vaccine triggers an immune response by analyzing the volunteers’ blood for antibodies.
However, If the vaccine works as designed, the immune system should generate antibodies that grab hold of a characteristic protein found on the surface of the novel coronavirus SARS-CoV-2.
Kaiser Permanente, the health care company conducting the trial said instead of introducing a dead or weakened virus into the body to prompt this reaction, as conventional vaccines do, the vaccine instructs cells to build the viral protein themselves using a molecule called messenger RNA (mRNA). Once utilized by the body, the mRNA should break down and be eliminated, leaving only protective antibodies behind.
PHASE 2 TRIAL:
According to the U.S. Centers for Disease Control and Prevention (CDC), the drug must then be tested in larger groups of people and over longer periods of time, in Phase 2 and Phase 3 trials.
Phase 2 trials typically examine several hundred people and monitor participants for periods of from several months to two years.
Worthy of note, Phase 2 trials serve as a secondary measure of safety and help researchers to refine the dosing of a particular medication. At this stage, researchers select participants with characteristics, such as age and physical health, that match those of the people who the vaccine is being developed for. (For example, although anyone can contract COVID-19, those of advanced age and those with chronic conditions are more likely to develop severe symptoms, so this could be a consideration in Phase 2 trials.)
PHASE 3 TRIAL:
According to the FDA, Phase 3 trials typically follows 300 to 3,000 volunteers over the course of one to four years; with a larger group of people, researchers can take note of unusual side effects of the drug, and by lengthening the study period, they can catch long-term side effects as they emerge.
Phase 3 trials must demonstrate that a given drug provides the medical benefits it’s intended to; if this coronavirus vaccine passes that test, the FDA could approve the drug for widespread use.
PHASE 4 TRIAL:
Following approval by the FDA, drugs undergo Phase 4 clinical trials, otherwise known as “post-marketing surveillance trials.” Once a drug enters public use, researchers monitor several thousand volunteers to spot side effects not seen in earlier trials and to track how well the vaccine works over extended periods of time, according to the National Cancer Institute.
Although this coronavirus vaccine may or may not reach Phase 4 trials in the coming years, limited studies have shown promising results. In the meantime, research groups around the world will continue to develop alternate vaccines to combat the spread of COVID-19.
The commission says it adopts scientific research methods to gather data, analyze trends in line with the dynamism of the industry and advise government.
NBC receives, processes and considers applications for the establishment, ownership or operation of radio and television stations including cable television service, direct satellite broadcast and others
Woman Crashes Ceremony with Kids to Stop her Husband from Getting Married to another Lady
Woman crashes ceremony with kids to stop her husband from getting married to another lady
A video of a woman disrupting the wedding ceremony of her supposed husband has since gone viral.
In the video, the woman is seen storming the ceremony with her children claiming she was still married to the groom.
The woman who is seen carrying a baby on her back, beckons on the other children to come into the ceremony
The video which was shared on Instagram shows the moment a lady disrupted a wedding, claiming to be married to the groom. What was meant to be one of the happiest days in the life of a lady turned out to be pretty embarrassing and devastating when her groom’s huge secret was exposed.
The woman claimed that she was still married to the groom. Sharing her story, she claimed they weren’t divorced, and there was no issue between them.
Regina Daniels, Ned Nwoko spotted having fun as they squash marriage crisis rumour (video) She added that she didn’t know why he should be getting married to another lady while she already had children with him.
the special day for a bride and groom was reported to have erupted in drama after a former lover of the groom stormed the church causing the bride to collapse.
The incident reportedly occurred in Benin City, Edo state. When the groom identified as Dele and his bride, Blessing, decided to tie the knot at the International Pentecostal Holiness Church in Benin City, they would never have foreseen the drama that occurred.
According to reports, the groom’s lover was said to have walked into the church and proceeded to the altar where she grabbed the microphone from the pastor.
Ahead of the debate, polls showed Harris is the only candidate at the top of the ticket with a net-positive favorability rating – on average in national polls, more Americans knew her positively than negatively.
Pence’s favorability is lagging – an average of 48% view him unfavorably, and 43% favorably per an average from Real Clear Politics.